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Background
Altered modulation of cGMP levels in brain seems to be
responsible for the impairment of some types of cognitive
function [1]. The homeostasis of cGMP is also strongly
altered in blood in patients with liver disease, who show
increased plasma cGMP but reduced cGMP content in
lymphocytes [2]. Activation of soluble guanylate cyclase
by NO is also altered in lymphocytes of patients with liver
cirrhosis [2]. This suggests that alterations in cGMP home-
ostasis in blood could reflect the alterations in brain and
be therefore associated with the appearance of minimal
hepatic encephalopathy (MHE). The aim was to assess
whether there is a correlation between the alterations in
different parameters involved in modulation of cGMP lev-
els and the presence of MHE.
Methods
We studied in 46 patients with liver cirrhosis and 26 con-
trols the performance in the PHES battery of psychometric
tests, critical flicker frequency (CFF), cGMP in plasma and
lymphocytes, activation of guanylate cyclase by NO in
lymphocytes, ammonia, nitric oxide metabolites and
atrial natriuretic peptide (ANP).
Results
Activation of guanylate cyclase by NO in lymphocytes and
cGMP in plasma were higher and CFF lower in patients
with than without MHE. Ammonia, ANP and metabolites
of nitric oxide were higher in patients than in controls but
were no different in patients with or without MHE (Fig-
ures 1, 2, 3, 4; Table 1).
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Critical flicker frequencyFigure 1
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Alteration in activation of guanylate cyclase by NO in lym-
phocytes correlates with PHES performance, CFF and
ammonia levels (Table 2). This suggests that altered mod-
ulation of guanylate cyclase by NO in lymphocytes would
reflect a parallel alteration in brain occurring in patients
with MHE that would be involved in their cognitive
impairment.
NO-induced increase in cGMP in lymphocytesFigure 4




Basal cGMP in lymphocytesFigure 3
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Table 1: Values of the different parameters analyzed in controls and in patients.
PARAMETERS CONTROLS Media ± SD (n) PATIENTS WITHOUT MHE p 
vs. Control
PATIENTS WITH MHE P 
vs. control
PATIENTS WITH MHE p 
vs. without MHE





(n = 22) p < 0.001 **
0.025 ± 0.015
(n = 12) p < 0.001 **
p > 0.05





(n = 23) p < 0.001 **
47 ± 18
(n = 12) p < 0.001 ***
p < 0.05 *
cGMP in Plasma (μM) 4.4 ± 1.7
(n = 17)
12 ± 4
(n = 24) p < 0.001 **
18 ± 4
(n = 12) p < 0.001 ***
p < 0.001 **
Nitrates + Nitrites (μM) 22 ± 9
(n = 26)
31 ± 13
(n = 31) p < 0.05*
38 ± 14
(n = 13) p < 0.001 ***
p = 0.09
(ns)
ANP in Plasma (pg/ml) 78 ± 13
(n = 13)
119 ± 25
(n = 14) p < 0.001 **
140 ± 50
(n = 9) p < 0.001**
p = 0.193
(ns)
Ammonia concentration (μM) 76 ± 30
(n = 23)
156 ± 86
(n = 23) p = 0.001 ***
151 ± 51
(n = 9) p < 0.001 ***
p = 0.89
(ns)
CFF (Hz) 46 ± 3
(n = 26)
41 ± 3
(n = 24) p < 0.001 ***
33 ± 4
(n = 15) p < 0.001 **
p < 0.001 **






p < 0.001 **
Age 43 ± 12 50 ± 8 55 ± 11 p > 0.05
(ns)
Table 2: Correlations between different parameters analysed.
CORRELATION WITH
PARAMETER PHES CFF AMMONIA
cGMP in plasma NO
p = 0.06, r = -0.235
YES
p = 0.004, r = -0.368
YES
p = 0.011, r = 0.386
cGMP in lymphocytes NO
p = 0.67, r = -611
YES
p = 0.029, r = -0.281
NO
p = 0.28, r = -0.165
Activation of sGC by
NO
YES
p = 0.004, r = -0.369
YES
p < 0.0001, r = -0.544
YES
p = 0.003, r = 0.433
Ammonia NO
p = 0.28, r = -0.156
YES
p = 0.021, r = 0.333Page 3 of 3
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